Drug intelligence / Profile preview

ITOP3

Development stage: Preclinical
Lead developer: Infinitopes
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

ITOP3 is an off-the-shelf, peptide-based cancer vaccine currently in preclinical development by Infinitopes. It is designed to stimulate the immune system to recognize and target specific tumor-associated antigens. As an off-the-shelf therapeutic, ITOP3 aims to provide a standardized treatment option that does not require the patient-specific customization typical of some other cancer vaccine platforms. The specific malignancy targeted by ITOP3 has not been publicly disclosed by the developer, though it is part of a broader pipeline of precision immunotherapies intended to address various solid tumors.

Targets

NeoAg-HLA-I (Neoantigen peptide–HLA class I complex)CD8+ T-cell receptor recognizing ITOP3 neoantigen peptide–HLA complexHLA-B7

Beyond the preview

Go deeper on ITOP3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ITOP3.

Explore the full profile